2023-504746-54-00Not yet recruitingPhase 1
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Oct 2023 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 27 Jun 2023
- Start date
- 1 Sept 2023
- Lead sponsor
- Tranquis Therapeutics Inc.
- Diseases
- ALS (motor neurone disease)
- EU CT number
- 2023-504746-54-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 16
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pauls Stradins Clinical University Hospital | Riga | Latvia | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.